New Year and Chrismas Offer
eClinical Solutions Market

eClinical Solutions Market Size, Share & By Product (Clinical Analytics Platform, CTMS, Clinical Data Integration Platform, eTMF, eCOA, Safety Solutions, EDC and CDMS, RTMS, Others), By Mode of Delivery (Licensed Enterprise (On-premise), Web-hosted (On-demand), Cloud-based (SaaS)), By Clinical Trial Phase (Phase I, Phase II, Phase III, Phase IV), By End User (Pharmaceutical and Biopharmaceutical Companies, Consulting Service Companies, Medical Device Manufacturers, Contract Research Organizations, Academic Research Institutions, Hospitals), and by Regions | Global Market Forecast 2022-2028

Report Id: SNS/HC/1764 | June 2022 | Region: Global | 125 Pages

Report Scope & Overview:

eClinical Solutions Market Size was valued at USD 7.34 billion in 2021, and is expected to reach USD 17.81 billion by 2028, and grow at a CAGR of 13.5 % over the forecast period 2022-2028.

To help speed up the clinical design process, eClinical solutions manage clinical experience and techniques. An eClinical arrangement is a mechanized arrangement (programming or potentially equipment) that upholds clinical testing tasks via computerizing beforehand manual tasks. With an expansion in clinical preliminaries in the drug and biotechnology businesses, the requirement for eClinical arrangements is expanding.

eClinical Solutions Market Revenue Graph

There is indeed a significant trend of exporting eClinical solutions due to the large patient pool and inexpensive operational costs in emerging nations such as Korea, Taiwan, and India. A clinical trial management system commonly sends data to a business intelligence system, which acts as a digital dashboard for trial managers. As they can collect and organise data that may be shared with multiple care providers and disseminated across multiple systems, clinical trial management systems are both cost and time effective. Electronic health records, electronic permission forms, integrating technologies, electronic data capture, and clinical data management systems are all part of eClinical solutions. By assuring effective management of the lengthy clinical research procedure, e-clinical solutions aid researchers in the end-to-end clinical research process. Because of technical improvements and government incentives, the market for eClinical solutions is increasing. It helps clinical research companies with team collaboration, regulatory document management, supply chain management, site performance monitoring, and reporting, all of which are expected to drive demand for eClinical solutions during the forecast period.

MARKET DYNAMICS

DRIVERS

  • Biopharmaceutical and pharmaceutical companies are increasing their R&D spending.

  • Clinical research studies are becoming more expensive to conduct due to rising operational costs and regulatory restrictions.

  • Clinical Trials Expenditure Is Increasing

  • Chronic Diseases Are Getting Worse

  • Smart Devices are being used more frequently in healthcare administration.

RESTRAINTS

  • Clinical Trials are in short supply due to a scarcity of healthcare professionals and patients.

  • Data security and privacy

  • eClinical systems are known for their high implementation costs.

OPPORTUNITIES

  • Clinical research activities in rising Asian countries are becoming more active.

  • Increasing Precision Medicine Research and Development

  • The rise of precision medicine is expected to revolutionise the global market for eclinical solutions.

CHALLENGES

  • Concerns about patient privacy

IMPACT OF COVID-19

The COVID-19 pandemic has prompted the healthcare and life sciences industries to think creatively about how to advance the best, most competent solutions, methods, and processes to assist clinical researchers in introducing safe and effective treatments to the public faster. As a result, many life sciences organisations are attempting to capitalise on this momentum and alter their processes. The desire to use all available resources, technologies, and digital capabilities to complete clinical trials more quickly and effectively is propelling the eclinical solution software industry forward. The push for decentralised trials, with protocol designs, technology, and methods that provide more significant remote input in research, is a critical initiative for the pandemic.

Clinical studies are being stalled and postponed in order to finish the coronavirus pandemic, which is putting heart disease, cancer, and diabetes research on the back burner. Many companies have communicated clinical trial disruptions due to the outbreak since March of this year. By emphasising compliance, safety, and a risk-based strategy, data services are expected to improve eclinical solutions revenue. As a result of the COVID-19 epidemic, trial participation has decreased dramatically.

By Product:

Due to the increasing importance of high-quality clinical data, eCOA is expected to be the fastest-growing market during the projection period. eCOA aids in the preservation of overall quality and is becoming more widely used in the measurement of patient-, clinician-, and observer-reported outcomes. The data gathering process on eCOA platforms improves the quality of data collected, improves data collection methods, and allows for better data analysis.

By Mode of Delivery:

The segment's prominence can be due to associated benefits such ease of access, usability, and cheaper investment requirements. Because web-hosted goods are highly configurable, providers can tailor information display for different user groups. These products also have a higher level of compatibility. All through the forecast period, the category is expected to hold its position.

Due to integrated features like flexibility, high accessibility, low handling costs, and quick data backup, the cloud-based category is expected to grow at an exponential CAGR of 13.5 percent over the projection period. These systems deliver real-time data, allowing users to make quick decisions and give high-quality information for risk-based monitoring. The need for cloud-based systems is expected to increase as a result of these benefits.

By Clinical Trial Phase: 

The segment's rise is being fueled by the increasing need for clinical data management software to reduce overall costs and increase process efficiency. The segment's growth is being aided by an increasing number of medications successfully advancing to phase III. The efficacy of a medicine is studied in Phase III with a group of more than 1,000 patients. Even as patients in a study grows, so does the difficulty of the study, which drives demand for computer-based data management systems and accelerates adoption of eClinical solutions.

Due to the great importance of these systems in predicting future outcomes and eliminating medication candidates with the lowest potential of success, the phase I segment is expected to be the most promising section over the forecast period. The discovery of novel medications is booming thanks to advances in biological modelling systems and customized medicine technology. The segment's growth is likely to be fueled by a huge number of phase I trials and the complicated management and analysis of data collected during diverse investigations.

By End User:

In 2021, the CROs category dominated the market for eClinical solutions, with a revenue share of more than 37%. The segment is expected to develop at a significant CAGR during the forecast period, owing to pharmaceutical companies' growing desire to cut overall spending. The growing use of eClinical solutions in research is expanding the segment's potential. The expanded development of this fragment may be ascribed to the upsides of re-appropriating clinical preliminaries to CROs. Cost reserve funds, expanded help effectiveness, expanded efficiency, and a more noteworthy spotlight on key improvement regions essential to an organization's prosperity are only a couple of the up-sides. Over the projection period, the pharma and biotech companies’ industry is expected to grow significantly. This is due to researchers' growing use of eClinical technologies, which improve clinical trials and reduce research workload. Biotechnology and pharmaceutical organisations can use technologies like this to identify clinical trial procedure bottlenecks. As a result, researchers in pharmaceutical and biotechnology organisations are increasingly looking for eClinical solution for clinical research programmes.

COMPETITIVE LANDSCAPE

Some of the major key players are as follows: Bioclinica, CRF Health, Dassault Systemes, Datatrak International, Inc., ERT Clinical, eClinicalWorks, Oracle, Parexel International Corporation, and other players.

KEY MARKET SEGMENTATION:

By Product:

  • Clinical Analytics Platform

  • Clinical Trial Management Systems (CTMS)

  • Clinical Data Integration Platform

  • Electronic Trail Master Files (eTMF)

  • Electronic Clinical Outcome Assessment (eCOA)

  • Safety Solutions

  • Electronic Data Capture (EDC) and Clinical Data Management Systems (CDMS)

  • Randomization and Trial Supply Management (RTMS)

  • Others

By Mode of Delivery:

  • Licensed Enterprise (On-premise)

  • Web-hosted (On-demand)

  • Cloud-based (SaaS)

By Clinical Trial Phase:

  • Phase I

  • Phase II

  • Phase III

  • Phase IV

By End User:

  • Pharmaceutical and Biopharmaceutical Companies

  • Consulting Service Companies

  • Medical Device Manufacturers

  • Contract Research Organizations

  • Academic Research Institutions

  • Hospitals

eClinical Solutions Market Segment Chart

REGIONAL ANALYSIS

In 2020, North America held the highest proportion of the global eClinical solutions market. Rising government regulations to help clinical preliminaries, continuous item upgrades and new item dispatches by vital participants in the eClinical arrangement market, and an expansion in the quantity of organizations for novel medication improvement are driving interest for eClinical arrangements in this area.

REGIONAL COVERAGE:

  • North America

    • USA

    • Canada

    • Mexico

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • The Netherlands

    • Rest of Europe

  • Asia-Pacific

    • Japan

    • south Korea

    • China

    • India

    • Australia

    • Rest of Asia-Pacific

  • The Middle East & Africa

    • Israel

    • UAE

    • South Africa

    • Rest of Middle East & Africa

  • Latin America

    • Brazil

    • Argentina

    • Rest of Latin America

eClinical Solutions Market Report Scope:
Report Attributes Details
Market Size in 2021 US$ 7.34 Billion
Market Size by 2028 US$ 17.81 Billion
CAGR CAGR of 13.5% From 2022 to 2028
Base Year 2021
Forecast Period 2022-2028
Historical Data 2017-2020
Report Scope & Coverage Market Size, Segments Analysis, Competitive  Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook
Key Segments • By Product (Clinical Analytics Platform, CTMS, Clinical Data Integration Platform, eTMF, eCOA, Safety Solutions, EDC and CDMS, RTMS, Others)
• By Mode of Delivery (Licensed Enterprise (On-premise), Web-hosted (On-demand), Cloud-based (SaaS))
• By Clinical Trial Phase (Phase I, Phase II, Phase III, Phase IV)
• By End User (Pharmaceutical and Biopharmaceutical Companies, Consulting Service Companies, Medical Device Manufacturers, Contract Research Organizations, Academic Research Institutions, Hospitals)
Regional Analysis/Coverage North America (USA, Canada, Mexico), Europe
(Germany, UK, France, Italy, Spain, Netherlands,
Rest of Europe), Asia-Pacific (Japan, South Korea,
China, India, Australia, Rest of Asia-Pacific), The
Middle East & Africa (Israel, UAE, South Africa,
Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America)
Company Profiles Bioclinica, CRF Health, Dassault Systemes, Datatrak International, Inc., ERT Clinical, eClinicalWorks, Oracle, Parexel International Corporation, and other players.
DRIVERS • Biopharmaceutical and pharmaceutical companies are increasing their R&D spending.
• Clinical research studies are becoming more expensive to conduct due to rising operational costs and regulatory restrictions.
• Clinical Trials Expenditure Is Increasing
RESTRAINTS • Clinical Trials are in short supply due to a scarcity of healthcare professionals and patients.
• Data security and privacy
• eClinical systems are known for their high implementation costs.


Frequently Asked Questions (FAQ) :

Top-down, bottom-up, Quantitative, Qualitative Research, Descriptive, Analytical, Applied, Fundamental Research.

Licensed Enterprise (On-premise), Web-hosted (On-demand), Cloud-based (SaaS) are the sub segments of by Mode of Delivery.

Key drivers of the eClinical Solutions Market the demand for low-cost drug discovery and development is growing, and Supporting Regenerative Medicine Research with Public and Private Funding.

Segments of eClinical Solutions market are By Product, By Mode of Delivery, By Clinical Trial Phase, and By End User.

eClinical Solutions Market Size was valued at USD 7.34 billion in 2021, and expected to reach USD 17.81 billion by 2028, and grow at a CAGR of 13.5 % over the forecast period 2022-2028.


Table of Contents

 

1. Introduction

1.1 Market Definition

1.2 Scope

1.3 Research Assumptions

 

2. Research Methodology

 

3. Market Dynamics

3.1 Drivers

3.2 Restraints

3.3 Opportunities

3.4 Challenges

 

4. Impact Analysis

4.1 COVID 19 Impact Analysis

4.2 Impact of Ukraine ware

 

5. Value Chain Analysis

 

6. Porter’s 5 forces model

 

7.  PEST Analysis

  

8. eClinical Solutions Market Segmentation, By Product

8.1 Clinical Analytics Platform

8.2 Clinical Trial Management Systems (CTMS)

8.3 Clinical Data Integration Platform

8.4 Electronic Trail Master Files (eTMF)

8.5 Electronic Clinical Outcome Assessment (eCOA)

8.6 Safety Solutions

8.7 Electronic Data Capture (EDC) and Clinical Data Management Systems (CDMS)

8.8 Randomization and Trial Supply Management (RTMS)

8.9 Others

 

9. eClinical Solutions Market Segmentation, By Mode of Delivery

9.1 Licensed Enterprise (On-premise)

9.2 Web-hosted (On-demand)

9.3 Cloud-based (SaaS)

 

10. eClinical Solutions Market Segmentation, By Clinical Trial Phase

10.1 Phase I

10.2 Phase II

10.3 Phase III

10.4 Phase IV

 

11. eClinical Solutions Market Segmentation, By End User

11.1 Pharmaceutical and Biopharmaceutical Companies

11.2 Consulting Service Companies

11.3 Medical Device Manufacturers

11.4 Contract Research Organizations

11.5 Academic Research Institutions

11.6 Hospitals

 

12. Regional Analysis

12.1 Introduction

12.2 North America

12.2.1 USA

12.2.2 Canada

12.2.3 Mexico

12.3 Europe

12.3.1 Germany

12.3.2 UK

12.3.3 France

12.3.4 Italy

12.3.5 Spain

12.3.6 The Netherlands

12.3.7 Rest of Europe

12.4 Asia-Pacific

12.4.1 Japan

12.4.2 South Korea

12.4.3 China

12.4.4 India

12.4.5 Australia

12.4.6 Rest of Asia-Pacific

12.5 The Middle East & Africa

12.5.1 Israel

12.5.2 UAE

12.5.3 South Africa

12.5.4 Rest

12.6 Latin America

12.6.1 Brazil

12.6.2 Argentina

12.6.3 Rest of Latin America

 

13 Company Profiles

13.1 Bioclinica

13.1.1 Financial

13.1.2 Products/ Services Offered

13.1.3 SWOT Analysis

13.1.4 The SNS view

13.2 CRF Health

13.3 Dassault Systemes

134 Datatrak International, Inc.

13.5 ERT Clinical

13.6 eClinicalWorks

13.7 Oracle

13.8 Parexel International Corporation

 

14 Competitive Landscape

14.1 Competitive Benchmark

14.2 Market Share analysis

14.3 Recent Developments

 

15 Conclusion

 

An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.

Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.

 

The 5 steps process:

Step 1: Secondary Research:

Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.

Secondary Research

Step 2: Primary Research

When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data.  This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.

We at SNS Insider have divided Primary Research into 2 parts.

Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.

This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.

Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.

Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.

Step 3: Data Bank Validation

Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.

Step 4: QA/QC Process

After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.

Step 5: Final QC/QA Process:

This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.